Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-2310 ◽

2018 ◽

Vol 24 (13) ◽

pp. 3097-3107 ◽

Cited By ~ 107

Author(s):

Zhe Yang ◽

Nong Yang ◽

Qiuxiang Ou ◽

Yi Xiang ◽

Tao Jiang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Resistance Mechanisms ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Lung Cancer Patients

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

10.2139/ssrn.3321505 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m ◽

Clinical Strategy

A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-2595 ◽

2021 ◽

pp. clincanres.2595.2021

Author(s):

Qing Zhou ◽

Lin Wu ◽

Pei Hu ◽

Tongtong An ◽

Jianying Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

10.2139/ssrn.3294124 ◽

2018 ◽

Author(s):

Qing Zhou ◽

Xiao-Qing Liu ◽

Pei Hu ◽

Jian-Ying Zhou ◽

Li Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Chinese Patients ◽

Third Generation ◽

Small Cell Lung ◽

Phase 1 Clinical Trial ◽

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

10.2139/ssrn.3341474 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr T790m ◽

Clinical Strategy

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8013 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8013-8013 ◽

Cited By ~ 15

Author(s):

Daniel Shao-Weng Tan ◽

Takashi Seto ◽

Natasha B. Leighl ◽

Gregory J. Riely ◽

Lecia V. Sequist ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Phase I Study ◽

Kinase Inhibitor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer

10.2139/ssrn.3495608 ◽

2019 ◽

Author(s):

James Chih-Hsin Yang ◽

D. Ross Camidge ◽

Cheng-Ta Yang ◽

Jianying Zhou ◽

Renhua Guo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase 1 ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Previously Treated ◽

Egfr Mutant

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Annals of Oncology ◽

10.1093/annonc/mdz437.001 ◽

2019 ◽

Vol 30 ◽

pp. ix158 ◽

Cited By ~ 3

Author(s):

Y.-L. Wu ◽

T.S.K. Mok ◽

J.-Y. Han ◽

M.-J. Ahn ◽

A. Delmonte ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Study ◽

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Investigational New Drugs ◽

10.1007/s10637-019-00732-4 ◽

2019 ◽

Vol 37 (6) ◽

pp. 1207-1217

Author(s):

Makoto Nishio ◽

Haruyasu Murakami ◽

Yuichiro Ohe ◽

Toyoaki Hida ◽

Hiroshi Sakai ◽

...

Keyword(s):

Lung Cancer ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Third Generation ◽

Small Cell Lung ◽

Epidermal Growth

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

10.1158/1538-7445.am2020-ct190 ◽

2020 ◽

Author(s):

Shun Lu ◽

Qiming Wang ◽

Guojun Zhang ◽

Xiaorong Dong ◽

Cheng-Ta Yang ◽

...

Keyword(s):

Kinase Inhibitor ◽

Phase Ii Study ◽

Locally Advanced ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

Open Label ◽

The Third ◽